Corvus Pharmaceuticals (CRVS) Stock Forecast, Price Target & Predictions
CRVS Stock Forecast
Corvus Pharmaceuticals stock forecast is as follows: an average price target of $10.67 (represents a 19.22% upside from CRVS’s last price of $8.95) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CRVS Price Target
CRVS Analyst Ratings
Buy
Corvus Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 13, 2024 | Roger Song | Jefferies | - | - | 227.46% | 45.25% |
Oct 22, 2024 | Graig Suvannavejh | Mizuho Securities | - | - | 58.73% | 34.08% |
Aug 18, 2023 | Jeff Jones | Oppenheimer | - | - | 219.65% | -21.79% |
10
Corvus Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 2 | 2 |
Avg Price Target | $13.00 | $12.50 | $12.50 |
Last Closing Price | $8.95 | $8.95 | $8.95 |
Upside/Downside | 45.25% | 39.66% | 39.66% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 13, 2024 | Jefferies | Buy | Buy | Hold |
May 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Aug 18, 2023 | Oppenheimer | Outperform | Initialise |
10
Corvus Pharmaceuticals Financial Forecast
Corvus Pharmaceuticals Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Corvus Pharmaceuticals EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Corvus Pharmaceuticals Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-9.12M | $-8.67M | $-8.23M | $-8.23M | $-7.74M | $-7.34M | $-6.87M |
High Forecast | $-9.12M | $-8.67M | $-8.23M | $-8.23M | $-6.45M | $-7.34M | $-6.87M |
Low Forecast | $-9.12M | $-8.67M | $-8.23M | $-8.23M | $-8.38M | $-7.34M | $-6.87M |
Surprise % | - | - | - | - | - | - | - |
Forecast
Corvus Pharmaceuticals SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Corvus Pharmaceuticals EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.14 | $-0.13 | $-0.12 | $-0.12 | $-0.12 | $-0.11 | $-0.12 |
High Forecast | $-0.14 | $-0.13 | $-0.12 | $-0.12 | $-0.10 | $-0.11 | $-0.12 |
Low Forecast | $-0.14 | $-0.13 | $-0.12 | $-0.12 | $-0.13 | $-0.11 | $-0.12 |
Surprise % | - | - | - | - | - | - | - |
Forecast
Corvus Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
XFOR | X4 Pharmaceuticals | - | - | 979.41% | Buy |
INZY | Inozyme Pharma | - | - | 422.06% | Buy |
PDSB | PDS Bio | - | - | 330.62% | Buy |
ABOS | Acumen Pharmaceuticals | - | - | 195.36% | Buy |
DAWN | Day One Biopharmaceuticals | - | - | 182.80% | Buy |
TERN | Terns Pharmaceuticals | - | - | 146.11% | Buy |
MREO | Mereo BioPharma Group | - | - | 81.45% | Buy |
HOOK | HOOKIPA Pharma | - | - | 39.53% | Buy |
CRVS | Corvus Pharmaceuticals | - | - | 19.22% | Buy |